Actively Recruiting
Effect of Neuromodulation on Pain Biomarkers and Functional Outcome in Patients With Fibromyalgia Syndrome
Led by Ahmed Alshimy · Updated on 2024-08-06
40
Participants Needed
1
Research Sites
43 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Fibromyalgia is the third most common musculoskeletal condition in terms of prevalence, after lumbar pain and osteoarthritis. Its prevalence is around 2-4 % and is more frequent in women than in men; the prevalence is highest in age the range of 40-60 years.
CONDITIONS
Official Title
Effect of Neuromodulation on Pain Biomarkers and Functional Outcome in Patients With Fibromyalgia Syndrome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with fibromyalgia of both genders
- Fibromyalgia duration longer than 6 months with a history of cervical or lumbar pain
- Age between 25 and 35 years old
- Medically stable with cognitive ability to understand instructions (Montreal Cognitive Assessment score >26)
You will not qualify if you...
- Neurological diseases such as stroke, multiple sclerosis, Parkinson's disease, or motor neuron disease
- Presence of a pacemaker
- History of spinal fusion in cervical or lumbar regions
- Metal implants in the spine
- Pregnancy
- Epilepsy
- Severe psychiatric disorders or substance abuse
- Unstable medical conditions affecting safety or study results
- Uncontrolled blood pressure or diabetes
- Visual or auditory problems
- Active inflammatory conditions
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Al Ryada University for Science and Technology
Sadat, Menoufia, Egypt
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
FACTORIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here